Senchukova MA, Kalinin EA, Volchenko NN. Predictors of disease recurrence after radical resection and adjuvant chemotherapy in patients with stage IIb-IIIa squamous cell lung cancer: A retrospective analysis. World J Exp Med 2024; 14(1): 89319 [PMID: 38590307 DOI: 10.5493/wjem.v14.i1.89319]
Corresponding Author of This Article
Marina A Senchukova, MD, PhD, Professor, Department of Oncology, Orenburg State Medical University, Sovetskaya Street, 6, Orenburg 460000, Russia. masenchukova@yandex.com
Research Domain of This Article
Oncology
Article-Type of This Article
Retrospective Cohort Study
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Exp Med. Mar 20, 2024; 14(1): 89319 Published online Mar 20, 2024. doi: 10.5493/wjem.v14.i1.89319
Predictors of disease recurrence after radical resection and adjuvant chemotherapy in patients with stage IIb-IIIa squamous cell lung cancer: A retrospective analysis
Marina A Senchukova, Evgeniy A Kalinin, Nadezhda N Volchenko
Marina A Senchukova, Department of Oncology, Orenburg State Medical University, Orenburg 460000, Russia
Evgeniy A Kalinin, Department of Thoracic Surgery, Orenburg Regional Cancer Clinic, Orenburg 460021, Russia
Nadezhda N Volchenko, Department of Pathology, P. A. Hertzen Moscow Oncology Research Centre, National Medical Research Centre of Radiology, Moscow 125284, Russia
Author contributions: Senchukova MA designed and performed the research, and wrote the paper; Kalinin EA acquired and analyzed the data and contributed substantially to the conception and design of the study; Volchenko NN participated in the discussion of related data, and revised and approved the final version; all the authors wrote and approved the final manuscript.
Institutional review board statement: This study was reviewed and approved by Ethics Committee of Orenburg State Medical University (Russia, Orenburg).
Informed consent statement: Patients were not required to give informed consent to the study because the study was retrospective and analysis used anonymous clinical data that were obtained after each patient agreed to treatment by written consent.
Conflict-of-interest statement: The authors have no financial relationships to disclose.
Data sharing statement: Data from patients included in the study in Statistica10 table or Excel table format can be provided upon request to the corresponding author at masenchukova@yandex.com.
STROBE statement: The authors have read the STROBE Statement – checklist of items, and the manuscript was prepared and revised according to the STROBE Statement – checklist of items.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Marina A Senchukova, MD, PhD, Professor, Department of Oncology, Orenburg State Medical University, Sovetskaya Street, 6, Orenburg 460000, Russia. masenchukova@yandex.com
Received: October 27, 2023 Peer-review started: October 27, 2023 First decision: December 7, 2023 Revised: December 20, 2023 Accepted: January 10, 2024 Article in press: January 10, 2024 Published online: March 20, 2024 Processing time: 143 Days and 23.6 Hours
ARTICLE HIGHLIGHTS
Research background
Establishing predictors of lung cancer (LC) recurrence is highly important both for determining the optimal treatment plan for the patients and for evaluating its effectiveness.
Research motivation
Assessment of different types of tumor microvessels, features of the tumor parenchyma and stroma can improve the accuracy of predicting the risk of lung squamous cell carcinoma (LSCC) recurrence.
Research objectives
This study aimed to establish predictors of disease recurrence after radical resection and adjuvant chemotherapy in patients with stage IIb-IIIa LSCC.
Research methods
This retrospective analysis of the treatment results of 69 patients with stage IIb-IIa LSCC who underwent radical surgery and received adjuvant chemotherapy. To establish independent predictors of the risk of LSCC recurrence, univariate and multivariate analyzes were performed, which included clinicopathological characteristics of LSCC and the features of tumor parenchyma and stroma.
Research results
The following independent predictors of a high risk of disease recurrence in patients with stage IIb-IIa LSCC were established: A low degree of tumor differentiation; metastases in regional lymph nodes; the presence of loose, fine-fiber connective tissue in the tumor stroma; and fragmentation of the tumor solid component.
Research conclusions
A method has been developed that allows us to identify a group of patients at high risk of disease recurrence and to adjust to ongoing treatment.
Research perspectives
Future studies will contribute to understanding the mechanisms of tumor progression and drug resistance of LSCC.
